title: Restless legs syndrome in narcolepsy: a side effect of sodium oxybate?
abstract: Gamma-hydroxybutyrate (GHB) has re-emerged as a major treatment for narcolepsy. As dopaminergic transmission is clearly involved in the pathophysiology of restless legs syndrome (RLS), and GHB reduces dopamine release, one may hypothesize that RLS may occur in narcolepsy in the presence of GHB. We report a case of narcolepsy with a severe occurrence of typical RLS with GHB, symptoms never previously experienced by the subject and reversible after withdrawal.
authors.affiliation: Service de Neurologie, Hôpital Gui-de-Chauliac, 34295 Montpellier, France.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Abril
authors.forename: Bertrand
authors.initials: B
authors.lastname: Carlander
authors.forename: Jacques
authors.initials: J
authors.lastname: Touchon
authors.forename: Yves
authors.initials: Y
authors.lastname: Dauvilliers
mesh_terms: D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D009290:Narcolepsy / Q000188:drug therapy*; D012148:Restless Legs Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D012978:Sodium Oxybate / Q000627:therapeutic use*
chemical_list: D012978:Sodium Oxybate